Instem acquires Xybion Digital

Instem has completed its acquisition of Xybion Digital, creator of the Pristima™ preclinical study management platform and Autoscribe Informatics.

31 July 2025 – Boston, MA; Staffordshire, UK, Instem today announced the closing of an acquisition of Xybion Digital (“Xybion”). Xybion is best known for its Pristima™ preclinical study management platform. Like Instem, Xybion has primarily focused on serving life sciences customers, particularly CROs, Pharmas, and Biotechnology firms.

The core solution, Pristima™, is an advanced and cloud-based SaaS study management platform tailored to facilitate primarily GLP preclinical research. Xybion also has solutions in the LIMS space through its Autoscribe™ brand, for R&D Quality Management (Xybion QMS™), and an advisory services arm. Xybion’s software solutions and consulting services serve customers on a global scale, with active customers in over 30 countries across 5 continents.

“The combination of these two companies effectively creates a ‘new Instem’ in the preclinical R&D space – a leader with unparallelled scale and talent enabling us to better focus on our mission to help our customers make discoveries, and to accelerate and advance their research programs. We will also now have more resources to devote to innovation and toward delighting customers. We believe this is a truly transformational development in the field of preclinical life sciences R&D. I also want to take this opportunity to welcome Xybion’s employees to Instem and express how delighted I am that we are joining forces.” Vik Krishnan, CEO, Instem.

The acquisition of Xybion adds many new large and industry-leading customers in the pharmaceutical and CRO spaces.

The combination allows Instem to meet the needs of all life sciences users in preclinical study management. Instem is further supported in its mission with Xybion’s experienced staff in this space. “We are excited about the future after joining forces to solve complex R&D projects in the regulated GLP environment,” further said Mr. Krishnan.